Featured Research

from universities, journals, and other organizations

Drug trial shows promise for treating constipation caused by pain medicines

Date:
June 4, 2014
Source:
University of Michigan Health System
Summary:
Taking medicines for chronic pain can often lead to constipation, but a study shows a daily pill can get things moving again. Globally, approximately 28 million to 35 million, or nearly half, of patients taking opioids for long-term pain develop constipation. Patients get sub-optimal results from laxatives.

Pain medicines often lead to constipation for patients seeking long-term pain relief, but an investigational once-daily drug may help, according to study led by the University of Michigan Health System.

Related Articles


Globally, approximately 28 million to 35 million, or nearly half, of patients taking opioids for long-term pain develop constipation. Patients get sub-optimal results from laxatives.

The results of two pivotal Phase 3 studies -- KODIAC-4 and KODIAC-5 of naloxegol, an investigational treatment for opioid-induced constipation (OIC) -- were published online first in the New England Journal of Medicine.

A 25 mg dose of the investigational drug naloxegol safely increased bowel movements among opioid-induced constipation sufferers, compared to a placebo, and the effects were maintained over a 12-week treatment period.

"The studies showed rapid and sustained improvement for these patients, without compromising their pain management," says lead study author and gastroenterologist William Chey, M.D., professor of internal medicine at the U-M Health System.

Naloxegol is an investigational peripherally-acting mu-opioid receptor antagonist, which has been specifically designed for the treatment of opioid-induced constipation (OIC), a common and often debilitating side effect of prescription medicines used to treat osteoarthritis and chronic back pain.

Opioids play an important role in chronic pain relief by binding to mu-receptors in the brain, blocking the brain's ability to perceive brain. But they also bind to mu-receptors in the bowel, contributing to constipation.

Naloxegol is designed to block the binding of opioids to receptors in the gastrointestinal tract without impacting the opioid receptors in the brain.

The Phase 3 studies enrolled 652 people in one trial and 700 in another. The 12-week, multicenter, randomized, double blind, placebo-controlled pivotal trials evaluated 12.5 mg and 25 mg doses of naloxegol, once-daily.

The most commonly reported adverse effects with naloxegol were abdominal pain, diarrhea, nausea, vomiting, flatulence and appeared to be dose-ordered, occurring more commonly in the 25 mg group.

Most adverse events were mild to moderate in severity and occurred shortly after initiation of naloxegol. There was one major cardiovascular adverse event in the 25 mg treatment group, one in the 12.5 mg treatment group and two among those in the placebo group.


Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


Journal Reference:

  1. William D. Chey, Lynn Webster, Mark Sostek, Jaakko Lappalainen, Peter N. Barker, Jan Tack. Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain. New England Journal of Medicine, 2014; 140604140030004 DOI: 10.1056/NEJMoa1310246

Cite This Page:

University of Michigan Health System. "Drug trial shows promise for treating constipation caused by pain medicines." ScienceDaily. ScienceDaily, 4 June 2014. <www.sciencedaily.com/releases/2014/06/140604202102.htm>.
University of Michigan Health System. (2014, June 4). Drug trial shows promise for treating constipation caused by pain medicines. ScienceDaily. Retrieved November 25, 2014 from www.sciencedaily.com/releases/2014/06/140604202102.htm
University of Michigan Health System. "Drug trial shows promise for treating constipation caused by pain medicines." ScienceDaily. www.sciencedaily.com/releases/2014/06/140604202102.htm (accessed November 25, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, November 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com
Madagascar Working to Contain Plague Outbreak

Madagascar Working to Contain Plague Outbreak

AFP (Nov. 24, 2014) Madagascar said Monday it is trying to contain an outbreak of plague -- similar to the Black Death that swept Medieval Europe -- that has killed 40 people and is spreading to the capital Antananarivo. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com
Are Female Bosses More Likely To Be Depressed?

Are Female Bosses More Likely To Be Depressed?

Newsy (Nov. 24, 2014) A new study links greater authority with increased depressive symptoms among women in the workplace. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins